semaj83/ctmatch_classification huggingface dataset:
Patient description: The patient is a 60 year old man complaining of frequent headaches, generalized bone pain and difficulty chewing that started 6 years ago and is worsening. Examination shows bilateral swellings around the molars. The swellings have increased since his last examination. Several extraoral lesions are detected in the head and face. The swellings are non-tender and attached to the underlying bone. Further evaluation shows increased uptake of radioactive substance as well as an increase in urinary pyridinoline. His serum alkaline phosphatase is 300 IU/L (the normal range is 44- 147 IU/L). His family history is only significant for hypertension in his mother and DM type 2 in his father. The diagnosis of Paget's Disease of Bone was confirmed and Bisphosphonate will be started as first-line therapy.

Clinical trial eligibility criteria: eligible ages (years): 20.0-80.0,  Thyroid Diseases Age 20-80 years old Thyroid diseases, including nodular goiter, hyperthyroidism, hypothyroidism and thyroid cancer (before or after operation), consecutive follow-up in outpatient department, and we expected to enroll 800 patients in one year, and follow-up with observation for 5 years  N/A
Patient description: The patient is a 60 year old man complaining of frequent headaches, generalized bone pain and difficulty chewing that started 6 years ago and is worsening. Examination shows bilateral swellings around the molars. The swellings have increased since his last examination. Several extraoral lesions are detected in the head and face. The swellings are non-tender and attached to the underlying bone. Further evaluation shows increased uptake of radioactive substance as well as an increase in urinary pyridinoline. His serum alkaline phosphatase is 300 IU/L (the normal range is 44- 147 IU/L). His family history is only significant for hypertension in his mother and DM type 2 in his father. The diagnosis of Paget's Disease of Bone was confirmed and Bisphosphonate will be started as first-line therapy.

Clinical trial eligibility criteria: eligible ages (years): 40.0-999.0,  Osteoarthritis hip or knee osteoarthritis (tibiofemoral), uni or bilateral, symptomatic, with confirmed diagnosis according to American College of Rheumatology ACR and European League Against Rheumatism (EULAR) Kellgren and Laurence radiological stage at least 2  knee or hip prosthesis on painful joint preceding osteotomy serious comorbidity (affecting quality of life, or leading to a high care consumption) according to X-ray : knee pain with isolated patello-femoral osteoarthritis (i.e without an associated tibiofemoral osteoarthritis) other pathology on knee or hip adults getting a legal protection or with the incapacity to give their consent
Patient description: The patient is a 60 year old man complaining of frequent headaches, generalized bone pain and difficulty chewing that started 6 years ago and is worsening. Examination shows bilateral swellings around the molars. The swellings have increased since his last examination. Several extraoral lesions are detected in the head and face. The swellings are non-tender and attached to the underlying bone. Further evaluation shows increased uptake of radioactive substance as well as an increase in urinary pyridinoline. His serum alkaline phosphatase is 300 IU/L (the normal range is 44- 147 IU/L). His family history is only significant for hypertension in his mother and DM type 2 in his father. The diagnosis of Paget's Disease of Bone was confirmed and Bisphosphonate will be started as first-line therapy.

Clinical trial eligibility criteria: eligible ages (years): 18.0-999.0,  Ostomy Hernia Signs and Symptoms Permanent or temporary active sigmoidostomy, transversostomy, jejunostomy or ileostomy PB diagnosed by stoma care nurse Ability to speak and understand Danish  Previous surgical repair for PB Major incisional abdominal hernias
Patient description: The patient is a 60 year old man complaining of frequent headaches, generalized bone pain and difficulty chewing that started 6 years ago and is worsening. Examination shows bilateral swellings around the molars. The swellings have increased since his last examination. Several extraoral lesions are detected in the head and face. The swellings are non-tender and attached to the underlying bone. Further evaluation shows increased uptake of radioactive substance as well as an increase in urinary pyridinoline. His serum alkaline phosphatase is 300 IU/L (the normal range is 44- 147 IU/L). His family history is only significant for hypertension in his mother and DM type 2 in his father. The diagnosis of Paget's Disease of Bone was confirmed and Bisphosphonate will be started as first-line therapy.

Clinical trial eligibility criteria: eligible ages (years): 0.0-999.0,  Neoplasm, Trophoblastic Gestational Trophoblastic Disease Hydatidiform Mole Hydatidiform Mole, Invasive Patients are eligible if they have a histologically proven trophoblastic disease, or a diagnosis of gestational trophoblastic neoplasia done on an abnormal evolution of hCG  none
Patient description: The patient is a 60 year old man complaining of frequent headaches, generalized bone pain and difficulty chewing that started 6 years ago and is worsening. Examination shows bilateral swellings around the molars. The swellings have increased since his last examination. Several extraoral lesions are detected in the head and face. The swellings are non-tender and attached to the underlying bone. Further evaluation shows increased uptake of radioactive substance as well as an increase in urinary pyridinoline. His serum alkaline phosphatase is 300 IU/L (the normal range is 44- 147 IU/L). His family history is only significant for hypertension in his mother and DM type 2 in his father. The diagnosis of Paget's Disease of Bone was confirmed and Bisphosphonate will be started as first-line therapy.

Clinical trial eligibility criteria: eligible ages (years): 18.0-70.0,  Heart Failure With Normal Ejection Fraction Preserved left ventricular systolic function on echocardiography (LVEF>50%) Evidence of diastolic dysfunction by echocardiography (E/e'>15) Symptoms of heart failure NT-proBNP levels >300 pg/ml absence of permanent atrial fibrillation  acute multi-organ failure history of any malignant disease within 5 years diminished functional capacity due to non-cardiac co-morbidities (COPD, PAOD, morbid obesity) pregnancy
Patient description: The patient is a 60 year old man complaining of frequent headaches, generalized bone pain and difficulty chewing that started 6 years ago and is worsening. Examination shows bilateral swellings around the molars. The swellings have increased since his last examination. Several extraoral lesions are detected in the head and face. The swellings are non-tender and attached to the underlying bone. Further evaluation shows increased uptake of radioactive substance as well as an increase in urinary pyridinoline. His serum alkaline phosphatase is 300 IU/L (the normal range is 44- 147 IU/L). His family history is only significant for hypertension in his mother and DM type 2 in his father. The diagnosis of Paget's Disease of Bone was confirmed and Bisphosphonate will be started as first-line therapy.

Clinical trial eligibility criteria: eligible ages (years): 18.0-999.0,  Morbid Obesity Obesity Diabetes Dyslipidemia Hypertension underwent LSG for morbid obesity and related morbidities as a primary procedure  previous history of obesity surgery
Patient description: The patient is a 60 year old man complaining of frequent headaches, generalized bone pain and difficulty chewing that started 6 years ago and is worsening. Examination shows bilateral swellings around the molars. The swellings have increased since his last examination. Several extraoral lesions are detected in the head and face. The swellings are non-tender and attached to the underlying bone. Further evaluation shows increased uptake of radioactive substance as well as an increase in urinary pyridinoline. His serum alkaline phosphatase is 300 IU/L (the normal range is 44- 147 IU/L). His family history is only significant for hypertension in his mother and DM type 2 in his father. The diagnosis of Paget's Disease of Bone was confirmed and Bisphosphonate will be started as first-line therapy.

Clinical trial eligibility criteria: eligible ages (years): 18.0-999.0,  Medication-related Osteonecrosis of the Jaw Bisphosphonate-Associated Osteonecrosis of the Jaw Age > 18 years Newly diagnosed patients with osteonecrosis in a facial bone other than the jaw, or Newly diagnosed patients with non-exposed MRONJ (stage 0), or Newly diagnosed patients with exposed MRONJ, i.e Current or previous treatment with antiresorptive or antiangiogenic agents Exposed bone or bone that can be probed through an intraoral or extraoral fistula(e) in the maxillofacial region that has persisted for more than 8 weeks No history of radiation therapy to the jaws or obvious metastatic diseases of the jaw Ability to understand the content of the patient information/ Informed Consent Form Willingness and ability to participate in the clinical investigation according to the Registry Plan (RP) Signed and dated IRB/EC-approved written informed consent  Recent history of substance abuse (i. e., recreational drugs, alcohol) that would preclude reliable assessment Pregnancy or women planning to conceive within the registry period Prisoner Participation in any other medical device or medicinal product study within the previous month that could influence the results of the present registry
Patient description: The patient is a 60 year old man complaining of frequent headaches, generalized bone pain and difficulty chewing that started 6 years ago and is worsening. Examination shows bilateral swellings around the molars. The swellings have increased since his last examination. Several extraoral lesions are detected in the head and face. The swellings are non-tender and attached to the underlying bone. Further evaluation shows increased uptake of radioactive substance as well as an increase in urinary pyridinoline. His serum alkaline phosphatase is 300 IU/L (the normal range is 44- 147 IU/L). His family history is only significant for hypertension in his mother and DM type 2 in his father. The diagnosis of Paget's Disease of Bone was confirmed and Bisphosphonate will be started as first-line therapy.

Clinical trial eligibility criteria: eligible ages (years): 1.0-100.0,  Wound Infection Sugar Solution Patients conducted surgical operation in the hospital within 2 weeks. The wound had swelling and lots of secretions; 2. Except for the incision, primary surgical site has been recovered smoothly. Patients didn't accept secondary operation in the same site  Except for the wound that can't use healthy skin closure in Phase I
Patient description: The patient is a 60 year old man complaining of frequent headaches, generalized bone pain and difficulty chewing that started 6 years ago and is worsening. Examination shows bilateral swellings around the molars. The swellings have increased since his last examination. Several extraoral lesions are detected in the head and face. The swellings are non-tender and attached to the underlying bone. Further evaluation shows increased uptake of radioactive substance as well as an increase in urinary pyridinoline. His serum alkaline phosphatase is 300 IU/L (the normal range is 44- 147 IU/L). His family history is only significant for hypertension in his mother and DM type 2 in his father. The diagnosis of Paget's Disease of Bone was confirmed and Bisphosphonate will be started as first-line therapy.

Clinical trial eligibility criteria: eligible ages (years): 18.0-60.0,  Circumference Reduction Subject ≥18 and ≤60 years of age at the time of enrollment 2. Fat thickness of at least 1.5 cm in the outer thigh and/or flank (measured by calibrated caliper) 3. For women of child-bearing potential: negative urine pregnancy test 4. General good health confirmed by medical history and skin examination of the treated area 5. Subject understands the study requirements and the treatment procedures and provides written Informed Consent before any study-specific tests or procedures are performed  History of un-balanced hypertension, ischemic heart disease, valvular heart disease, congestive heart failure, pacemaker/defibrillator 2. Current hyperlipidemia, diabetes mellitus, hepatitis, liver disease, HIV positive status, blood coagulopathy or excessive bleeding, autoimmune or connective tissue disease 3. Having a permanent implant in the treated area, such as metal plates, or an injected chemical substance such as silicone 4. Previous liposuction in the treatment areas within 12 months 5. History of skin disease in the treatment area, known tendency to form keloids or poor wound healing 6. Abnormal kidney, liver or coagulation functions, abnormal lipid profile or blood count within the last 3 months 7. Childbirth within the last 12 months or women who are breastfeeding a child
Patient description: The patient is a 60 year old man complaining of frequent headaches, generalized bone pain and difficulty chewing that started 6 years ago and is worsening. Examination shows bilateral swellings around the molars. The swellings have increased since his last examination. Several extraoral lesions are detected in the head and face. The swellings are non-tender and attached to the underlying bone. Further evaluation shows increased uptake of radioactive substance as well as an increase in urinary pyridinoline. His serum alkaline phosphatase is 300 IU/L (the normal range is 44- 147 IU/L). His family history is only significant for hypertension in his mother and DM type 2 in his father. The diagnosis of Paget's Disease of Bone was confirmed and Bisphosphonate will be started as first-line therapy.

Clinical trial eligibility criteria: eligible ages (years): 50.0-70.0,  Herpes Zoster Fibrosis Cirrhosis of any etiology diagnosed clinically by labs and imaging or by liver biopsy Male or Female age 50 to 70  Active or history of Herpes Zoster Anaphylactic allergy to neomycin or gelatin Immunosuppressive medication use Antiviral medication use Known history of HIV Known immune deficiency disease Active on a liver transplant list Known malignancy other than non-melanomatous skin cancer within the past five years History of vaccination with varicella or zoster vaccine Pregnant or lactating women
Patient description: The patient is a 60 year old man complaining of frequent headaches, generalized bone pain and difficulty chewing that started 6 years ago and is worsening. Examination shows bilateral swellings around the molars. The swellings have increased since his last examination. Several extraoral lesions are detected in the head and face. The swellings are non-tender and attached to the underlying bone. Further evaluation shows increased uptake of radioactive substance as well as an increase in urinary pyridinoline. His serum alkaline phosphatase is 300 IU/L (the normal range is 44- 147 IU/L). His family history is only significant for hypertension in his mother and DM type 2 in his father. The diagnosis of Paget's Disease of Bone was confirmed and Bisphosphonate will be started as first-line therapy.

Clinical trial eligibility criteria: eligible ages (years): 18.0-100.0,  Valvular Heart Disease Stenosis and Regurgitation (Diagnosis) Presence of aortic stenosis, mitral or aortic regurgitation at the time of an echocardiography at the "Cliniques Universitaires Saint Luc"
Patient description: The patient is a 60 year old man complaining of frequent headaches, generalized bone pain and difficulty chewing that started 6 years ago and is worsening. Examination shows bilateral swellings around the molars. The swellings have increased since his last examination. Several extraoral lesions are detected in the head and face. The swellings are non-tender and attached to the underlying bone. Further evaluation shows increased uptake of radioactive substance as well as an increase in urinary pyridinoline. His serum alkaline phosphatase is 300 IU/L (the normal range is 44- 147 IU/L). His family history is only significant for hypertension in his mother and DM type 2 in his father. The diagnosis of Paget's Disease of Bone was confirmed and Bisphosphonate will be started as first-line therapy.

Clinical trial eligibility criteria: eligible ages (years): 0.0-18.0,  Papilledema Associated With Increased Intracranial Pressure Consecutive patients from the PED Aged 0-18 years Who require funduscopic examination and referred to ophthalmologic evaluation  Direct trauma to the eye with suspicion of ruptured globe or laceration of the eyelid History of glaucoma
Patient description: The patient is a 60 year old man complaining of frequent headaches, generalized bone pain and difficulty chewing that started 6 years ago and is worsening. Examination shows bilateral swellings around the molars. The swellings have increased since his last examination. Several extraoral lesions are detected in the head and face. The swellings are non-tender and attached to the underlying bone. Further evaluation shows increased uptake of radioactive substance as well as an increase in urinary pyridinoline. His serum alkaline phosphatase is 300 IU/L (the normal range is 44- 147 IU/L). His family history is only significant for hypertension in his mother and DM type 2 in his father. The diagnosis of Paget's Disease of Bone was confirmed and Bisphosphonate will be started as first-line therapy.

Clinical trial eligibility criteria: eligible ages (years): 0.0-999.0,  Umbilical Cyst Pilonidal Sinus no limitation  patients followed-up less than 2 years
Patient description: The patient is a 60 year old man complaining of frequent headaches, generalized bone pain and difficulty chewing that started 6 years ago and is worsening. Examination shows bilateral swellings around the molars. The swellings have increased since his last examination. Several extraoral lesions are detected in the head and face. The swellings are non-tender and attached to the underlying bone. Further evaluation shows increased uptake of radioactive substance as well as an increase in urinary pyridinoline. His serum alkaline phosphatase is 300 IU/L (the normal range is 44- 147 IU/L). His family history is only significant for hypertension in his mother and DM type 2 in his father. The diagnosis of Paget's Disease of Bone was confirmed and Bisphosphonate will be started as first-line therapy.

Clinical trial eligibility criteria: eligible ages (years): 18.0-70.0,  Osteoarthritis Currently scheduled for a bone marrow aspirate concentration (BMAC) procedure Cognitively able to give consent and complete the required questionnaires  History of leukemia or lymphoma History of any autoimmune disorders and disease Currently taking immunosuppressive medications Presence of an active or suspected infection, or an infection of the joint in question within the past 6 months Vulnerable populations (pregnant women and breast-feeding women) Cortisone injection into the affected joint within 6 weeks Used NSAIDs within 1 week of the procedure History of bleeding disorders or inflammatory joint disease Surgical intervention on the affected or contralateral joint within 6 months of BMAC injection
Patient description: The patient is a 60 year old man complaining of frequent headaches, generalized bone pain and difficulty chewing that started 6 years ago and is worsening. Examination shows bilateral swellings around the molars. The swellings have increased since his last examination. Several extraoral lesions are detected in the head and face. The swellings are non-tender and attached to the underlying bone. Further evaluation shows increased uptake of radioactive substance as well as an increase in urinary pyridinoline. His serum alkaline phosphatase is 300 IU/L (the normal range is 44- 147 IU/L). His family history is only significant for hypertension in his mother and DM type 2 in his father. The diagnosis of Paget's Disease of Bone was confirmed and Bisphosphonate will be started as first-line therapy.

Clinical trial eligibility criteria: eligible ages (years): 18.0-90.0,  Medication-related Osteonecrosis of the Jaw Bisphosphonate-related Osteonecrosis of the Jaw Avascular Necrosis Stage 1, 2, or 3 MRONJ as defined by the AAOMS Position Paper on Medication-Related Osteonecrosis of the Jaw-2014 Update (Ruggiero 2014). 2. History of exposure to antiresorptive medications such as bisphosphonates or RANK-L inhibitors 3. Absence of tumor in the jaw at the time of recruitment 4. Patients with the capacity to give informed consent  Patients with history of external radiation therapy to the jaws 2. Patients who underwent any surgical intervention for MRONJ in the past 4 months 3. Patients with past microvascular reconstruction of the head and neck 4. Patients with an expected survival less than 1 year 5. Patients with allergy or hypersensitivity to pentoxifylline, xanthines, or tocopherol 6. Patients with planned invasive dental procedure in the next year 7. Patients taking oral anticoagulants 8. Patients with known hemorrhagic and coagulation disorder 9. Patients with a vitamin K deficiency due to any cause 10. Female patients who are pregnant or lactating 11. Patients with history of serious bleeding or extensive retinal hemorrhage 12. Patients with ischemic heart diseases, including, but not limiting, recent myocardial infarction 13. Patients with serious cardiac arrhythmia 14. Patient with history of prostate cancer 15. Patients with severe liver disease 16. Patients with severe renal failure (Creatinine clearance <30 mL/min) 17. Patients with diagnosed hypotension 18. Patients taking CYP1A2 inhibitors (e.g. ciprofloxacin, fluvoxamine) 19. Diagnosis of MRONJ with no exposed bone 20. Patient cannot tolerate impressions of exposed bone in a clinical setting, if needed. 21. There is a change in the patient's clinical presentation (tooth extraction, sequestrectomy) from alginate impression, if impression is indicated. 22. Any other situation or condition that, in the opinion of the may interfere with optimal in the study 23. A patient who has taken both bisphosphonate and Denosumab
Patient description: The patient is a 60 year old man complaining of frequent headaches, generalized bone pain and difficulty chewing that started 6 years ago and is worsening. Examination shows bilateral swellings around the molars. The swellings have increased since his last examination. Several extraoral lesions are detected in the head and face. The swellings are non-tender and attached to the underlying bone. Further evaluation shows increased uptake of radioactive substance as well as an increase in urinary pyridinoline. His serum alkaline phosphatase is 300 IU/L (the normal range is 44- 147 IU/L). His family history is only significant for hypertension in his mother and DM type 2 in his father. The diagnosis of Paget's Disease of Bone was confirmed and Bisphosphonate will be started as first-line therapy.

Clinical trial eligibility criteria: eligible ages (years): 18.0-49.0,  Schistosomiasis Adults, male, 18 to 49 years old (inclusive) at the time of inclusion Living in one of selected villages in Saint-Louis Region (Senegal) Free of obvious/severe health problems except schistosomiasis, as established by clinical examination and blood analysis, i.e. hematological exams, liver and renal function tests Written informed consent to participate obtained Treated with 40mg/kg Praziquantel (PZQ) before (W-5 to W-4 before the first injection) in case of infection with S. mansoni and S. haematobium Residence in the area during the period of the study  Adult who does not respond to one of the Current or previous chronic administration (defined as more than 14 days) of immunosuppressive drugs or other immuno-modifying drugs Known hypersensitivity to any component in the Sm14 vaccine or history of allergic disease Knowledge of non-infectious chronic disease Acute disease at time of enrollment Other conditions which in opinion of the PI may potentially represent a danger for the patient to be enrolled Non residence in the study area or intent to move during the study period